Investor and Morgan Stanley acquire Molnlycke
Investor, the largest industrial holding company in the Nordic region, and Morgan Stanley Principal Investments have signed an agreement to acquire Molnlycke Health Care Group AB from Apax Partners for an enterprise value of 2.85 billion euros ($3.69 billion). The majority of the acquisition will be financed by external debt.
Molnlycke is a global single-use medical products company headquartered in Gothenburg, Sweden, which manufactures and sells wound care and surgical products primarily for the professional health care sector.
International law firm Freshfields Bruckhaus Deringer advised Investor and Morgan Stanley Principal Investments on the merger and acquisition aspects of the purchase, which will be made through an acquisition company equally controlled by Investor and MSPI, with Molnlycke's management as minority shareholders.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze